Roni Mamluk Selected Research

CT-322

3/2010	Anti-tumor effect of CT-322 as an adnectin inhibitor of vascular endothelial growth factor receptor-2.
11/2008	The Adnectin CT-322 is a novel VEGF receptor 2 inhibitor that decreases tumor burden in an orthotopic mouse model of pancreatic cancer.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Roni Mamluk Research Topics

Disease

5	Neoplasms (Cancer) 03/2010 - 01/2002
2	Inflammation (Inflammations) 03/2005 - 01/2005
2	Hypersensitivity (Allergy) 03/2005 - 01/2005
1	Acromegaly 04/2015
1	Carcinoma (Carcinomatosis) 03/2010
1	Glioblastoma (Glioblastoma Multiforme) 03/2010
1	Pancreatic Neoplasms (Pancreatic Cancer) 11/2008
1	Neoplasm Metastasis (Metastasis) 11/2008
1	Pulmonary Edema 03/2005
1	Edema (Dropsy) 01/2005
1	Vascular Malformations 03/2003
1	Hemorrhage 03/2003
1	Vascular System Injuries 01/2002

Drug/Important Bio-Agent (IBA)

2	CT-322IBA 03/2010 - 11/2008
2	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 11/2008 - 01/2005
1	Octreotide (Sandostatin)FDA LinkGeneric 04/2015
1	Phosphotransferases (Kinase)IBA 03/2010
1	temsirolimus FDA Link 03/2010
1	Sunitinib (Sutent)FDA Link 03/2010
1	Vascular Endothelial Growth Factor Receptor-2 (Vascular Endothelial Growth Factor Receptor 2)IBA 03/2010
1	Sorafenib (BAY 43-9006)FDA Link 03/2010
1	Gemcitabine FDA Link 11/2008
1	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA 11/2008
1	Interleukin-2 (IL2)IBA 03/2005
1	O-(Chloroacetylcarbamoyl)fumagillol (TNP 470)IBA 03/2005
1	AngiostatinsIBA 03/2005
1	Neuropilin-1IBA 03/2003
1	Semaphorin-3AIBA 01/2002
1	NeuropilinsIBA 01/2002
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2002
1	Transcription Factors (Transcription Factor)IBA 01/2002

Therapy/Procedure

1	Therapeutics 11/2008